Skip to main content
SpringerLink
Log in

Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Few studies have shown that host interleukin-28B (IL28B) genetic polymorphisms are associated with insulin resistance in patients with chronic hepatitis C virus (HCV) infection. However, the clinical relevance of this relationship is unclear.

Aims

We examined the association between IL28B genotype for rs12980275 and risk of type 2 diabetes and diabetes-related complications.

Methods

We used a cross-sectional study of prospectively recruited male veterans with chronic HCV. We employed logistic regression analysis and adjusted for patients’ age, race, body mass index, and hepatic fibrosis.

Results

A total of 528 participants were recruited (mean age 59.1 years; 38.5 % African-American; 40.3 % advanced fibrosis). Of these, 36.1 % were homozygous for favorable AA allele for rs12980275, 49.0 % were heterozygous (AG), and 14.0 % were homozygous for the unfavorable allele (GG). Prevalence of diabetes was significantly lower in patients with both favorable alleles (AA) than that with at least one unfavorable IL28B G allele (21.1 vs. 30.2 %, p = 0.02). Similarly, patients who were homozygous for the favorable alleles had lower prevalence of diabetes-related complications than patients with any unfavorable IL28B allele (5.7 vs. 12.2 %, p = 0.01). This association did not change after adjusting for sociodemographic characteristics, body mass index, and stage of hepatic fibrosis (adjusted ORdiabetes 0.56, 95 % CI 0.35–0.89; ORdiabetes-related complications 0.47, 95 % CI 0.23–0.96).

Conclusions

Patients who have favorable AA IL28B alleles have a lower prevalence of diabetes and related complications compared with patients with unfavorable IL28B rs12980275 genotype. IL28B genotype information may be used to counsel HCV patients regarding their individualized risk of diabetes and diabetes-related complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ge D, Fellay J, Thompson A, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.

    Article  CAS  PubMed  Google Scholar 

  2. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon- alpha and ribavirin therapy. Nat Genet. 2009;41:1100–1104.

    Article  CAS  PubMed  Google Scholar 

  3. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–1109.

    Article  CAS  PubMed  Google Scholar 

  4. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338–1345, 1345e1–1345e7.

  5. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol. 2009;86:23–32.

    Article  CAS  PubMed  Google Scholar 

  6. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol. 2011;2011:349575.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Stättermayer AF, Rutter K, Beinhardt S, et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol.. 2012;57:492–498.

    Article  PubMed  Google Scholar 

  8. Petta S, Rosso C, Leung R, et al. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clin Gastroenterol Hepatol.. 2013;11:311–317.

    Article  CAS  PubMed  Google Scholar 

  9. White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology.. 2012;55:759–768.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3:8.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008;32:22–39.

    Article  PubMed  Google Scholar 

  12. Monzillo LU, Hamdy O. Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev. 2003;61:397–412.

    Article  PubMed  Google Scholar 

  13. Malavolti M, Mussi C, Poli M, et al. Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21–82 years. Ann Hum Biol. 2003;30:380–391.

    Article  CAS  PubMed  Google Scholar 

  14. Medici G, Mussi C, Fantuzzi AL, Malavolti M, Albertazzi A, Bedogni G. Accuracy of eight-polar bioelectrical impedance analysis for the assessment of total and appendicular body composition in peritoneal dialysis patients. Eur J Clin Nutr. 2005;59:932–937.

    Article  CAS  PubMed  Google Scholar 

  15. Clinical Classifications Software (CCS) for ICD-9-CM. http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Last accessed April 2014

  16. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. Med Clin. 2001;117:530–533.

    Article  CAS  Google Scholar 

  17. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49:831–844.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Veldt BJ, Duarte-Rojo A, Thompson AJ, et al. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant. 2012;12:737–744.

    Article  CAS  PubMed  Google Scholar 

  19. Noureddin M, Wright EC, Alter HJ, et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology. 2013;58:1548–1557.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Sato M, Kondo M, Tateishi R, et al. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One. 2014;9:e91822.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This material is based upon work supported in part by a VA Clinical Research and Development Merit Review Award H-22934 (PI: El-Serag), a Helis Foundation grant (PI: Moore, Co-PI: El-Serag), the National Institute of Diabetes Digestive and Kidney Diseases (R03 DK095082, PI: White), a pilot award (PI: Kanwal) from the Texas Medical Center Digestive Disease Center (P30 Center Grant DK56338), and the Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413). Drs. White’s and El-Serag’s effort was supported in part by the National Institute of Diabetes Digestive and Kidney Diseases (K24 DK04-107 and K01 DK081736, respectively). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs, the National Institute of Diabetes Digestive and Kidney Diseases, or the Helis Foundation.

Conflict of interest

No conflicts of interest exist for any of the authors.

Author information

Authors and Affiliations

  1. Clinical Epidemiology and Comparative Effectiveness Program, Section of Health Services Research (IQuESt), Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, USA

    Fasiha Kanwal, Donna L. White, Li Jiao, Shahriar Tavakoli-Tabasi, David J. Ramsey, Jill Kuzniarek & Hashem B. El-Serag

  2. Section of Gastroenterology and Hepatology, Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX, USA

    Fasiha Kanwal, Donna L. White, Li Jiao & Hashem B. El-Serag

  3. Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA

    Fasiha Kanwal, Donna L. White, Li Jiao, Shubhada Sansgiry, David J. Ramsey, Jill Kuzniarek & Hashem B. El-Serag

  4. Texas Medical Center Digestive Disease Center, Houston, TX, USA

    Fasiha Kanwal, Donna L. White, Li Jiao & Hashem B. El-Serag

  5. Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

    Donna L. White & Li Jiao

  6. Section of Infectious Diseases, Hepatitis C Clinic, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

    Fasiha Kanwal, Donna L. White, Li Jiao, Shahriar Tavakoli-Tabasi, Shubhada Sansgiry, David J. Ramsey, Jill Kuzniarek, Andrew Spiegelman & Hashem B. El-Serag

  7. Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX, USA

    Shahriar Tavakoli-Tabasi

  8. Department of Defense and Veterans Administration Vision Center of Excellence, Washington, DC, USA

    Andrew Spiegelman

Authors
  1. Fasiha Kanwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donna L. White
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shahriar Tavakoli-Tabasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shubhada Sansgiry
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David J. Ramsey
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jill Kuzniarek
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrew Spiegelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hashem B. El-Serag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donna L. White.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kanwal, F., White, D.L., Jiao, L. et al. Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. Dig Dis Sci 60, 2030–2037 (2015). https://doi.org/10.1007/s10620-015-3545-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3545-8

Keywords

Search

Navigation